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INTRODUCTION
Brugada syndrome is an inherited cardiac disor-
der initially described in 1992 by Pedro and Josep
Brugada (1). It is traditionally identified by electro-
cardiograph (ECG) and is defined by right bundle-
branch block and ST segment elevation in the right
precordial leads (V1-V3), without evidence of any
underlying structural heart disease. Other symp-
toms can include : ventricular arrhythmias, syncope,
and sudden death (1, 2). The genetic abnormalities
that cause Brugada syndrome have been linked to
mutation in the ion channel genes which encodes
the α -subunit of the cardiac sodium channel (3).
General anesthetic management with Brugada syn-
drome is limited, however, careful anesthetic man-
agement is important to avoid inducing malignant
arrhythmias (4-7).
Electroconvulsive therapy (ECT) has an impor-
tant role in the treatment of severe and medication-
resistant major depression, mania, schizophrenia
and related psychotic disorders (8). When an elec-
trical current is applied to the brain via transcuta-
neous electrodes, the resultant electroencephalo-
graphic (EEG) spike and wave activity is accompa-
nied by a generalized tonic-clonic motor seizure
and acute cardiovascular response (8). The typical
cardiovascular response to ECT consists of transient
tachycardia and hypertension lasting approximately
5 minutes. The cardiovascular response is associ-
ated with the release of catecholamine and occa-
sional cardiac arrhythmias (9). This case report pre-
sents the general anesthetic management used for
a patient with Brugada ECG pattern for a series of
ECT.
CASE DESCRIPTION
A 61 year old male patient, 176 cm, 48 kg was
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scheduled for a series of ECT for severe major de-
pression. The patient was disoriented to place, apa-
thetic, poriomania, consciousness disorder, and
needed intravenous alimentation for lack of oral in-
take. Several adequate medical treatments had been
tried, however, were ineffective. The most recent
pharmacologic regimen for the treatment of his
mental disorder was 0.25 mg brotizoram, 5 mg levo-
mepromizine, 10 mg paroxetine, and 0.4 mg alprazo-
lam. Due to the patient’s current neurological state,
written consent was obtained from the patient’s
family.
On preoperative investigation, he had a 12-lead
ECG showing an incomplete right bundle block
and ST segment elevation in the precordial leads
(Figure 1). The patient had no history of cardiac
symptoms like arrhythmias or syncope, however,
his sister died suddenly due to unknown cardiac
events. Pre-operative echocardiography was normal
and the patient was diagnosed with Brugada ECG
pattern (type 2) by a licensed cardiologist.
His medical history included diabetes mellitus
with diet therapy, and hemorrhoidectomy which had
been performed under local anesthesia 19 years
before. Preoperative blood analysis and serum elec-
trolytes were all within normal limits.
The patient was anesthetized for each ECT, to-
taling ten events within 20 days. Electrocardiogra-
phy, blood pressure, pulse oximetry, body tempera-
ture and neuromuscular transmission at the adduc-
tor pollicis muscle using acceleromyography or train
of four (TOF) were monitored. The number of re-
sponses to the TOF stimuli indicates the degree of
neuromuscular blockade (10). Four twitches (T4)
of the TOF response mean to be able to move, three
twitches (T3) indicate intermediate acting muscle
relaxant, two twitches (T2) are suitable for short
term relaxation with approximate 80% of receptors
blocked, and one twitch (T1) and twitches absent
(T0) of the TOF are conditions for intubation or
long term mechanical ventilation. Each time, body
temperature was maintained and general anes-
thesia was induced with intravenous propofol (50
mg), followed by rocuronium (50 mg) after loss of
consciousness and the ventilation was assisted us-
ing a face mask and 100% oxygen. An arterial tour-
niquet was applied to the left leg of the patient to
isolate the left leg for motor seizure duration. An
electrical stimulus was delivered via bitemporal elec-
trodes. The duration of motor seizure was recorded
as the time from the electrical stimulus to cessa-
tion of tonic-clonic motor activity in the isolated leg.
Sugammadex (4 mg/kg) was administered to re-
verse neuromuscular block while monitoring TOF
at the appearance of T2. Spontaneous breathing re-
turned immediately and T4 of the TOF were ap-
peared. The patient was hemodynamically stable
and ECT was performed safely and effectively in all
treatments.
DISCUSSION
Anesthetic management of a patient with Brugada
ECG pattern deserves careful preoperative evalu-
ation and is essential to avoid inducing malignant
arrythmia. Sodium channel blockers such as procai-
namide and flecainide are contraindicated in the pa-
tients with Brugada ECG pattern (2). Additionally,
neostigmine and α -agonists augment ST elevation
without coronary spasm (11). Therefore, class IA
anti-arrhythmic drugs should be avoided and spe-
cial caution should be exercised when neostigmine
and α -agonists are used (4-7).
There is one case report on a patient without pre-
viously known cardiac abnormalities, who developed
asystole during ECT and was later diagnosed with
Brugada syndrome. In that case, it is uncertain
whether Brugada syndrome was the causative fac-
tor of asystole under ECT although the investiga-
tors did feel that Brugada was a risk factor when
determining whether ECT was the most appropriate
therapy (12). As a result, ECT in this patient was
Figure 1 : A 12- lead ECG with an incomplete right bundle block
and ST segment elevation in the precordial leads (V1 toV2).
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decided carefully as adequate intensity and length
of seizure is required for effective ECT (13), which
likely would result in transient tachycardia and hy-
pertension and possibly provoke malignant arrhyth-
mia and asystole.
In this case, propofol was used for induction of
anesthesia. Propofol has more anti-convulsant ef-
fects than other inductional agents, although meas-
urements of seizure quality after propofol anesthesia
were not significantly different (14, 15). Propofol
also has characteristics such as rapid emergence
from anesthesia, lower incidence of hypertension or
tachycardia. Due to these effects, propofol is pref-
erable for patients with Brugada ECG pattern.
Succinylcholine is the most commonly used mus-
cle relaxant to reduce the muscle contractions and
minimize injury and pain associated with ECT. How-
ever, even small doses of succinylcholine can pro-
duce side effects such as myalgia, hyperthermia,
and hyperkalemia (8). In this case, rocuronium
was administered to the patient. This short-acting,
amino-steroidal neuromuscular blocking agent has
a specific reversal agent, sugammadex. Sugam-
madex is the γ -cyclodextrin that encapsulates ro-
curonium. Cholinesterase inhibitor, neostigmine, is
ineffective if used in profound block and may not
completely reverse moderate block after 20 minutes
(16). However, sugammadex can easily and rapidly
reverse profound neuromuscular block at doses
greater than 2 mg/kg (17).
Brugada syndrome is an increasingly recognized
disorder with fatal consequences if not correctly
identified and addressed. Many drugs and treat-
ments can precipitate malignant arrhythmia or car-
diac effects. In this case we show that a combina-
tion of propofol, rocuronium and sugammadex can
effectively and safely be used for patients with
Brugada ECG pattern undergoing numerous cycles
of ECT.
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